Lovaltech

Lovaltech |
🧬 French biotech company specializing in the development of innovative nasal vaccines. Protecting the world, more effectively and more simply. 🛡️

[Lovaltech @lovaltech]

🧪 A successfully completed Phase I clinical trial
📅 Phase II scheduled for November 2026
🚀 And other projects in progress and coming soon…

#Deeptech #Vaccines #MucosalImmunity

[Lovaltech @lovaltech]

Lovaltech is :
✅ An exclusive global license
💰 €17 million in funding secured
🧬 A technology platform dedicated to nasal vaccination

[Lovaltech @lovaltech]

Vous avez été des centaines à croire en nous sur @tudigoFR. Merci !🙏

La campagne de financement de Lovaltech se clôture avec succès. Votre soutien est le moteur de notre innovation. Nous avons hâte de vous partager la suite de nos avancées.✨

#Crowdfunding #Innovation #Merci

[Lovaltech @lovaltech]

🧬 Phase I validated | €17M raised | Phase II underway (results by late 2027).

A 100% French breakthrough technology, proudly developed in the laboratories of the University of Tours and @INRAE_France. 🇫🇷🌱

#Deeptech #Vaccines #MucosalImmunity

[Lovaltech @lovaltech]

100% French research

A game-changer in the fight against viruses—through the nose, not the arm. 👃❌💉
For the past four years, Lovaltech has been developing a groundbreaking vaccine to block transmission — not just severe cases. 🎂

[Lovaltech @lovaltech]

Notre mission : cibler les muqueuses pour réduire drastiquement la transmission des agents infectieux.

Deadline pour investir ici ➡️ https://t.co/wuriP97DNV

#Innovation #Investissement #France2030

[Lovaltech @lovaltech]

🏁 Dernière ligne droite pour Lovaltech ! Objectifs dépassés avec +500 investisseurs mobilisés pour réinventer la vaccination par voie intranasale. Un immense merci. 🧬🔥

Pourquoi nous rejoindre avant la clôture ?

[Lovaltech @lovaltech]

Pour nous donner les moyens de :
🧪 Valider notre Phase II clinique
💻 Accélérer notre plateforme R&D
🩺 Faire avancer le programme #COVIDLong
🤝 Négocier nos partenariats et licences avec la pharma

[Lovaltech @lovaltech]

Décryptage dans @NR_Tours : 🔗 https://t.co/qDi28oRHXL

#HealthTech #Recherche #Deeptech

[Lovaltech @lovaltech]

L’#Hantavirus est au cœur de l’actualité. Notre plateforme pourrait-elle servir de base pour un vaccin nasal ? 🤔

Si nos priorités restent le #COVIDLong, la grippe et la préparation pandémique, nos technologies sont prêtes à pivoter en cas d'urgence. 🧪

[Lovaltech @lovaltech]

A great preparation for a stronger future for Lovaltech!

A big thank you to Euronext for the quality of their support throughout this demanding and inspiring journey. 👍

#IPOready #Euronext #StockMarket #Biotech

[Lovaltech @lovaltech]

Heading toward the future! 📈

Lovaltech is nearing the end of @euronext's IPOready program following a memorable penultimate session at their offices in La Défense.

A highlight of the event was the iconic symbol of going public: ringing the market bell. 🔔

[Lovaltech @lovaltech]

Why do we talk about global health (#OneHealth)?
🦠+🌱+👤

Because 75% of emerging human diseases originate in animals. Anticipating tomorrow’s needs requires looking at the living world as a whole.

This is Lovaltech’s scientific compass. 🚀

#Biotech #Prevention #EcoHealth

[Lovaltech @lovaltech]

Our teams tackle this technological challenge every day to develop more effective and sustainable protection. ✨

#Biotech #FutureOfHealth #Deeptech

[Lovaltech @lovaltech]

The key to preventing transmission lies not in reacting, but in anticipating. 🌍

Unraveling the complexities of viral spread is at the heart of our mission.

[Lovaltech @lovaltech]

It was a key opportunity to showcase our major breakthrough : a nasal vaccine that blocks the transmission of viruses. 🧬🛡️

🔜Next step: Monaco in September for a presentation to the local economic circle.

#DeepTech #PrinceOfMonaco #Immunology

[Lovaltech @lovaltech]

Proud to embody local innovation! 🚀

On May 6th, the President of @lovaltech attended a private dinner with H.S.H. Prince Albert II of Monaco and the Prefect of Indre-et-Loire.

[Lovaltech @lovaltech]

Together with our partners, we are developing a strategy based on mucosal immunity to address the root causes of persistent symptoms.

Acting today for tomorrow’s health. ✨

#Innovation #HealthTech #LongCovid

[Lovaltech @lovaltech]

Long COVID is not inevitable; it is a major medical challenge. 🩺

In response to the lack of effective treatment for millions of patients, Lovaltech is taking action.

[Lovaltech @lovaltech]

By stimulating their production right at the virus’s point of entry, Lovaltech aims to block transmission from the very first contact. No entry, no infection! 🚫🦠

#Lovaltech #Immunology #IgA #Innovation #Health

[Lovaltech @lovaltech]

🔍 Science Spotlight: Do you know about IgA?

While traditional antibodies circulate in the blood, IgA antibodies are the true “guardians” of our mucous membranes—especially those in the nose. 🛡️